Clinical trial
Clinical Study on the 2C3L Strategy Based on Marshall Venous Chemoablation for the Treatment of Persistent Atrial Fibrillation Combined With Heart Failure
NCT06438692 is registered in ClinicalTrials.gov with Qianfoshan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical Study on the 2C3L Strategy Based on Marshall Venous Chemoablation for the Treatment of Persistent Atrial Fibrillation Combined With Heart Failure
- Lead sponsor
- Qianfoshan Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- June 16, 2022
- Completion date
- June 16, 2025
- Enrollment
- 130 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.